RXRX vs SDGR
RXRX and SDGR side by side — valuation & fundamentals (public data).
Key statistics
| Metric | RXRXRECURSION PHARMACEUTICALS, INC. | SDGRSchrodinger, Inc. |
|---|---|---|
| Market cap | $2.38B | — |
| P/S | 33.2x | — |
| Revenue | — | $259.04M(TTM) |
| Revenue growth (YoY) | 26.9% | 23.3% |
| Net income | — | -$54.34M(TTM) |
| Earnings growth (YoY) | -39.1% | 44.8% |
| EPS, diluted | — | $-0.73(TTM) |
| EBIT margin | -867.9% | -65.2% |
| ROE | -71.2% | -31.4% |
| ROIC | -181.7% | — |
| 1y total return | -27.5% | +27.2% |
Figures from SEC filings · for reference only · not investment advice
Growth of $10,000: RXRX vs SDGR
| Metric | RXRX | SDGR |
|---|---|---|
| End value | $1.2K | $3.4K |
| Total return | -87.8% | -66.4% |
| CAGR | -31.5% | -17.8% |
| Volatility | 93.0% | 64.4% |
| Sharpe | -0.01 | -0.05 |
| Sortino | -0.02 | -0.08 |
| Max drawdown | -93.1% | -86.0% |
Based on 1394 common trading days, 2021-04-16 → 2026-11-02 · risk-free 4.21% (current short-Treasury, held constant)
A head-to-head total-return backtest over real split- and dividend-adjusted prices: how a one-time $10,000 investment in each stock, held to today, would have grown over their common window — including reinvested dividends. A disclosed historical statistic — NOT a prediction, a guarantee, or investment advice. Past performance does not predict future results.
Related comparisons
Delayed data · Public sources · For reference only · Not investment advice (this page declares no winner)